记者 吴越 去年11月，嘉定工业区牵头成立"嘉定区医疗健康产业链联盟"，构建覆盖项目招引、技术转化、市 场拓展、资金支持、政策对接的全流程服务体系。据介绍，通过产业链联盟整合链主企业、科研机构、 金融资本等多方资源，嘉定工业区打造"医企悦动"特色服务品牌，将分散的产业资源转化为集群优势， 既解决了中小企业单打独斗的资源瓶颈，又加速了产业链上下游的供需匹配，实现"招一个、带一串、 兴一片"的集聚效应。 "联影作为链主企业，将持续开放创新平台、共享产业资源，深化与嘉定及各方的合作联动，共同 推动国产高端医疗器械产业突破升级。"联影医疗总经理兼联席首席执行官谭国陞说，希望以大会为契 机，携手更多优质伙伴扎根联影小镇，聚力技术攻坚与产业协同，助力集聚区建设提质增效。 现场还公布了联影小镇医疗器械产业集聚区建设工作推进方案，聚焦"五个一"关键举措，全力推动 联影小镇"快出形象、早出功能"。构建一个产业生态体系，引育一批全链条服务平台，筹建一组双轨制 产业基金，拓展一个高能级品牌宣传矩阵，招引一批高质量的储备项目。 昨天，"医企悦动·聚势'链'影"联影产业链大会暨嘉定工业区医疗健康产业生态交流会举行。大会旨 在依托联影集 ...

Core Viewpoint - The biopharmaceutical sector is expected to experience significant performance divergence among its sub-sectors before the third quarter of 2025, with industry revenue and profit growth rates initially declining before rebounding, as the pressures from high baselines, centralized procurement, and anti-corruption measures have been largely absorbed [1] Group 1: Innovative Drugs - The commercial insurance innovation drug catalog is set to debut in 2025, which is anticipated to drive incremental payments for innovative drug products [2] - The domestic new drug development is accelerating, with lower costs and favorable macro policies, leading to a global leadership position in innovative drug development, contributing approximately one-third of the global innovative R&D pipeline by 2025 [2] - The overseas rights BD transactions are driving the revaluation of innovative drug assets, with a continuous increase in the proportion of Chinese innovative drug license-outs [2] Group 2: CXO and Life Sciences - The CXO market is witnessing improved supply-demand dynamics, with CDMO companies entering a high prosperity cycle due to strong demand for new molecules like ADCs and peptides [2] - The life sciences upstream sector is experiencing a comprehensive recovery in downstream demand, with listed companies actively pursuing mergers and acquisitions to expand [3] Group 3: AI in Healthcare - The "Artificial Intelligence+" policy is leading to widespread applications of AI in healthcare, with significant developments driven by companies like Deepseek [3] Group 4: High-end Medical Equipment - The high-end medical equipment sector is poised for growth due to domestic procurement recovery, import substitution, and accelerated international expansion [3] Group 5: Orthopedic Joint Consumables - The negative impact of centralized procurement is clearing, and the aging population is driving market expansion, with potential growth in surgical robotics [3] Group 6: Traditional Chinese Medicine - There are signs of operational improvement in traditional Chinese medicine, with factors like flu season and basic drug catalog adjustments potentially catalyzing a new market cycle [4]

Core Insights - The report highlights a significant shift in the pharmaceutical and biotechnology industry, moving from a follower to a leader in innovation, particularly in the context of international expansion and high-end product development [3][4] - The overall industry revenue and profit growth are expected to rebound after a period of decline, driven by the recovery of innovative drugs and the CXO sector [3][4] Industry Performance and Valuation Dynamics - In the first three quarters of 2025, the pharmaceutical sector experienced a notable divergence in performance across sub-sectors, with innovative drugs and CXO showing signs of recovery while others lagged [3][15] - The total revenue for 461 A-share listed companies in the pharmaceutical sector is projected to reach CNY 24,640 billion in 2024, with a slight decline of 0.7% year-on-year [15][18] - The overall valuation of the pharmaceutical sector remains low compared to historical averages, with innovative drugs benefiting from expectations of business development (BD) transactions [3][4][15] Innovative Drugs - The report emphasizes that the rapid development and lower costs of new drug development in China have positioned the country as a global leader, contributing approximately one-third of the global innovative R&D pipeline in 2025 [4][14] - The introduction of the commercial insurance innovative drug directory in 2025 is expected to stimulate payment growth for innovative drug products [3][4] CXO Sector - The CXO market is witnessing improved supply and demand dynamics, with CDMO companies entering a high-growth cycle due to strong demand for new molecular entities [4][15] - Key players in the CDMO space, such as WuXi AppTec, are highlighted for their robust project pipelines and market positioning [4][15] Life Sciences Upstream - The recovery in downstream demand is driving revenue growth in the life sciences sector, with companies actively pursuing mergers and acquisitions to expand their market presence [4][15] - Companies like Bide Pharmaceutical and Haoyuan Pharmaceutical are noted for their strong cash reserves and strategic acquisition activities [4][15] AI in Healthcare - The report discusses the impact of AI in healthcare, driven by government policies and the development of large-scale AI models, with companies like JD Health and Yimaitong being key players [4][5] High-End Medical Equipment - The high-end medical equipment sector is expected to benefit from a recovery in domestic procurement, import substitution, and accelerated international expansion [4][5] - Companies such as United Imaging and Kaili Medical are identified as potential beneficiaries of these trends [4][5] Orthopedic Consumables - The orthopedic market is expanding due to an aging population, with the negative impacts of centralized procurement clearing up, leading to a resurgence in demand for robotic-assisted surgeries [4][5] Traditional Chinese Medicine - Some traditional Chinese medicine companies are showing signs of revenue and profit improvement, driven by seasonal demand and adjustments in the essential medicine directory [4][5]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2]. Core Viewpoints - The recent performance of the pharmaceutical sector has been sluggish, with the innovative drug sector experiencing a significant rise in expectations earlier this year, now undergoing a correction. However, innovative medical devices are expected to benefit from ongoing government support for medical equipment upgrades and accelerated domestic replacement of high-end medical devices, alongside continuous expansion into overseas markets. A recovery is anticipated starting in Q3 2025, with performance gradually improving in 2026 [3][9]. - The high-end medical device sector is driven by the recovery of in-hospital procurement, suggesting a focus on companies such as United Imaging, Shandong Weigao, and Mindray Medical. The demand for consumer medical devices is gradually recovering, with a shift in market share from imported brands, indicating potential in companies like Kefu Medical and Yuyue Medical. The orthopedic consumables market has reached a price floor, with opportunities for market share growth in orthopedic robotics and overseas expansion, highlighting companies like Aikang Medical and Chuangli Medical [3][9]. - The pharmaceutical equipment sector is undergoing a cyclical recovery, with rapid overseas growth opening new avenues for growth. Domestic margins are expected to stabilize and profitability to improve, with a return to rational competition anticipated from late 2024. The recovery in innovative drug financing and frequent business development transactions are expected to drive a revival in contract manufacturing organizations (CMOs), positively impacting the pharmaceutical equipment industry. Additionally, global strategic safety backups and commitments from multinational pharmaceutical companies to invest in the U.S. market are projected to accelerate fixed asset expenditures in the pharmaceutical sector over the next three years, with a focus on companies like Senson International and Dongfulong [3][9]. - In the CXO and upstream life sciences supply chain, leading global CXO companies such as WuXi AppTec and Kanglong Huacheng are highlighted. Domestic clinical CRO leaders like Tigermed and Pruce are also recommended, along with resource-based CXOs such as Zhaoyan New Drug and Mediso. The upstream life sciences supply chain includes companies like Baipusais and Haier Biomedical [3][9]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's return was -1.04% last week, ranking 17th among 31 sub-industry indices. The medical services sub-sector had the highest weekly return at 1.67%, while the pharmaceutical commercial sub-sector had a return of -4.26% [3][9]. Industry Trends - The report emphasizes the ongoing low performance of the pharmaceutical sector, particularly in innovative drugs, while highlighting the potential recovery in innovative medical devices and the pharmaceutical equipment sector [3][9]. Recommendations - Specific companies to watch include United Imaging, Mindray Medical, Kefu Medical, and Aikang Medical in the high-end medical device sector, as well as Senson International and WuXi AppTec in the pharmaceutical equipment and CXO sectors [3][9].

新华财经上海12月15日电（记者李荣）依托联影集团链主资源，搭建高效对接平台，推动产业链补链强 链延链，构建协同共生的生物医药产业生态。在15日举行的联影产业链大会暨嘉定工业区医疗健康产业 生态交流会上，发布了上海联影小镇医疗器械产业集聚区建设推进方案。 去年11月，嘉定工业区牵头成立"嘉定区医疗健康产业链联盟"，以"要素互通、资源共享"为核心，构建 覆盖项目招引、技术转化、市场拓展、资金支持、政策对接的全流程服务体系，整合链主企业、科研机 构、金融资本等多方资源，将分散的产业资源转化为集群优势，既解决了中小企业单打独斗的资源瓶 颈，又加速了产业链上下游的供需匹配。 联影医疗相关负责人表示，联影作为链主企业，将持续开放创新平台、共享产业资源，深化与上海嘉定 及各方的合作联动，共同推动国产高端医疗器械产业的突破升级。 （文章来源：新华财经） ——引育一批全链条服务平台。通过招引、培育纳入一批具备全链条服务能力的重点平台，以"做好服 务端"为核心定位，依托"产业组织者"的优势资源，聚焦医疗企业需求搭建专业化服务生态。 ——筹建一组双轨制产业基金。发挥龙头企业在赛道研判、项目挖掘和投后赋能等方面的核心作用，共 同组 ...

Group 1 - The core viewpoint of the article highlights the performance and financial metrics of United Imaging Healthcare (688271) as of December 15, 2025, showing a stock price increase of 0.91% to 129.8 yuan with a trading volume of 46,200 hands and a total transaction amount of 600 million yuan [1] - The company reported a main revenue of 8.859 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 2.843 billion yuan, a 75.41% increase year-on-year, and a net profit attributable to shareholders of 122 million yuan, reflecting a 143.8% year-on-year growth [2] Group 2 - The company has a debt ratio of 30.08% and reported investment income of 606.847 million yuan, with financial expenses of -438.233 million yuan and a gross profit margin of 47.02% [2] - Over the past 90 days, 25 institutions have rated the stock, with 18 buy ratings and 7 hold ratings, and the average target price set by institutions is 173.12 yuan [2]

Core Viewpoint - The article discusses the increasing trend of companies voluntarily abandoning bids for medical equipment procurement projects in China, highlighting the complexities and challenges within the industry, including price competition and regulatory issues [2][12]. Group 1: Bid Abandonment Cases - In 2025, there has been a noticeable increase in cases of companies voluntarily abandoning bids in the medical equipment sector, with notable examples including GE Healthcare abandoning a bid just three days after winning [2][9]. - The case of WanDong Medical, which won a bid for a 1.5T MRI system at a price of 4 million yuan, is particularly striking as the company later chose to abandon the bid after a lengthy and complicated procurement process [4][12]. - The article notes that this year marks the fifth case of a medical equipment manufacturer abandoning a bid, indicating a troubling trend in the industry [9][12]. Group 2: Reasons for Bid Abandonment - Common reasons for voluntary bid abandonment include underestimating production capacity before bidding and discovering that the actual profit margins do not meet expectations after winning the bid [13][14]. - The practice of aggressive price competition, where companies submit low bids to win contracts, often leads to situations where the awarded price is unsustainable for project operation, prompting companies to abandon the bid [13][14]. - High-priced bids may also be abandoned if hospitals express concerns about the pricing, potentially leading to discussions that result in the company voluntarily withdrawing [13][14]. Group 3: Industry Dynamics and Challenges - The medical equipment procurement landscape has shifted towards centralized purchasing, which has significantly reduced costs but has also intensified price competition among manufacturers [20][21]. - The article highlights that the current environment is characterized by high inventory levels and a price war among manufacturers, which has led to declining revenues and profits for leading medical device companies [20][21]. - Regulatory bodies are taking action to address issues of price competition, with recent announcements aimed at maintaining fair market practices and preventing below-cost bidding [21].

Core Viewpoint - The recent reform in the fund industry emphasizes performance, leading to significant salary reductions for nearly a thousand fund managers if their products underperform by over 10 percentage points compared to benchmarks over the past three years and have negative profit margins [1]. Fund Performance and Management - According to Wind data, the three funds managed by Pang Wenjie have shown substantial negative returns over the past three years, with the North Trust Ruifeng Industrial Upgrade fund underperforming its benchmark by 58.31% and managing a scale of 0.71 billion [2][4]. - The North Trust Ruifeng Preferred Growth fund has underperformed by 45.87% with a scale of 0.23 billion, while the North Trust Ruifeng Health Life Theme fund has underperformed by 39.66% with a scale of 0.90 billion, totaling a management scale of only 1.84 billion [2][4]. Investment Focus and Market Conditions - The funds managed by Pang Wenjie focus on specific themes that have faced industry adjustments, including the new energy sector, consumer goods, and the medical innovation industry [4][5]. - The North Trust Ruifeng Industrial Upgrade fund heavily invests in the new energy supply chain, with major holdings in leading photovoltaic and wind power companies, which have recently experienced significant declines [4]. - The North Trust Ruifeng Preferred Growth fund focuses on the consumer sector, particularly in liquor and food and beverage industries, which have shown mixed performance recently [4][5]. - The North Trust Ruifeng Health Life Theme fund targets the medical innovation sector, which is also facing challenges, with major holdings in medical device companies that have seen declines [4]. Manager's Outlook and Strategy - Pang Wenjie maintains a relatively optimistic outlook for the market, emphasizing the potential recovery of the consumer sector and the benefits of monetary policy changes [5][6]. - He highlights the importance of adapting investment strategies to navigate market style changes and improve fund performance in light of the new salary regulations [6].

Core Insights - The establishment of Zhongbao Investment in December 2015 marked a new beginning for insurance funds as a significant source of long-term investment in China's financial system, with a current management scale exceeding 450 billion yuan [1] - Zhongbao Investment has focused on alternative investments over the past decade and plans to expand into secondary and overseas markets to support national strategies and develop a comprehensive asset management group [1] Investment in Technology - The recent listing of domestic GPU companies, including Moer Thread, highlights the significant market opportunities in the GPU sector, which has been dominated by foreign firms [3] - Zhongbao Investment has supported multiple domestic GPU enterprises, including Moer Thread, which has incurred R&D expenses of 5.122 billion yuan from 2020 to 2024, significantly exceeding its revenue during the same period [5] - The company has been actively investing in the technology industry, supporting firms like SMIC and United Imaging through long-term holdings and strategic investments to overcome critical technological challenges [6] Financial Support for Urban Development - Zhongbao Investment has played a crucial role in urban renewal projects, contributing 20 billion yuan to Shanghai Real Estate Group to facilitate the renovation of old residential areas, leveraging its investment to mobilize an additional 80 billion yuan in loans and social capital [9] - The company has also provided 5 billion yuan in debt investment for urban village renovation projects, significantly enhancing urban quality and functionality [9] Strategic Partnerships and Fund Establishment - In December 2024, Zhongbao Investment will establish the "Zhijichip Fund" in collaboration with partners, focusing on the integrated circuit industry to utilize the long-term investment capabilities of insurance funds [8] - The company has developed a diverse toolbox of investment products, including equity and debt instruments, to ensure that long-term capital is effectively utilized [8] Commitment to National Strategy - Zhongbao Investment has engaged in significant infrastructure projects, including overseas port constructions, with a cumulative cooperation scale of 48 billion yuan, demonstrating its commitment to supporting local industry development [10] - The company aims to align its operations with national strategies by establishing large-scale, long-term fund products that serve as a stabilizing force for economic development [10] Transformation and Future Strategy - Zhongbao Investment is undergoing a transformation to become a pioneer in new finance, focusing on the principles of rational, value, and long-term investments while avoiding short-term speculation [11][12] - The company has outlined a new development strategy for 2025, emphasizing a comprehensive approach to asset management and investment, with a focus on supporting high-level technological self-reliance [14] Social Responsibility and Community Engagement - Since 2019, Zhongbao Investment has been involved in poverty alleviation efforts in Inner Mongolia, transitioning to support local economic development and ensuring sustainable growth [18] - The company emphasizes the importance of integrating social responsibility into its business model, aiming to enhance community welfare while achieving financial objectives [18]

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].